Insights

  • Date

  • Content Type

  • Reset

Blog

The regulatory environment for the development of mRNA vaccines during COVID-19

7.12.20

By Ciaran Greene

A growing interest in mRNA-based technologies over the last decades has allowed the rapid development and deployment of...

Read More

Blog

Covid and consultancy – combating a global health crisis with unprecedented scientific and regulatory solutions

1.12.20

By Michael Pfleiderer

2020 certainly exceeded everybody’s expectations in any major area of everyday life and work. Read our leading vaccine...

Read More

Blog

Biomarkers in drug development: a double-edged sword?

30.11.20

By Mariya Gromova and Aleksandra Nevmerzhitskaya

In the 21st century the term biomarkers is no longer strictly associated with disease diagnostics, instead the evolving...

Read More

Blog

Vaccine Development in Paediatric Populations – How to Proceed for SARS-CoV-2 Vaccines?

5.11.20

By Jerry Fuady

While adult clinical trials of SARS-CoV-2 vaccines have rapidly moved into Phase 3, no clinical trials have been...

Read More

Blog

In Vitro Diagnostics (IVD) Development in Times of the Corona-Crisis

28.10.20

By Maximilian Strunz

The “second wave” of the global COVID-19 pandemic is currently evolving at fast speed. While the news report...

Read More

Blog

How to manage the risk of foreign visible particles in ATMPs

22.10.20

By Elena Meurer and Noemi Lupo

Being free of visible particles is a must for parenteral products. However, occurrence of visible particles in ATMPs...

Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more